KRAS G12C

Impact of KRAS G12D and concurrent mutations on NSCLC outcomes. Our cohort shows 15.6% mKRAS (32, 32, 14% for G12C, G12D and G12V), G12D is associated with female and a lower smoking rate (pack/year). @incanMX @AndresFCardonaZ @Ecaballep https://t.co/YVgxHYVNAZ (@ogarrieta)

🎯🧬 Cracking KRASG12C across all solid tumors: the new kid on the block for tissue-agnostic precision medicine ⁦@ESMO_Open⁩ ⁦@myESMO⁩ ⁦@cczielinski⁩ https://t.co/c9tG8T7FJ4 (@VivekSubbiah)

Great point- might broaden to EVERYONE with adv NSCLC as now we can act on common alterations, eg KRas G12C too! CtDNA is a great but tricky tool-it lets u see the tip of the iceberg So if u see it- act on it but if not clearly informative, don’t let it steer your pt’s TITANIC! (@DrSteveMartin)

Cracking KRASG12C across all solid tumors: the new kid on the block for tissue-agnostic precision medicine ⁦@ESMO_Open⁩ ⁦@myESMO⁩ ⁦@OncoAlert⁩ https://t.co/c9tG8T7FJ4 (@VivekSubbiah)

Interested in the latest in #CARTcelltherapy and treatment of HER2+ #esophagogastriccancer and KRAS-G12 C-mutant #NSCLC? You'll find brief summaries of work by @MSKCancerCenter's @jaeparkmd, @YJanjigianMD, @SteveMaronMD, @rohit_thum, + @KCArbourMD here. https://t.co/GDzcsZ7csG (@MSK_DeptOfMed)

The @AACR GENIE BPC is an impressive resource with 1846 annotated NSCLC cases with NGS from 2014-18, described @CCR_AACR. In this dataset, 44% had an actionable alteration (20% #EGFR, 13% #KRAS G12C). Free access to explore! @NouraChoudhury @RielyMD https://t.co/2kGkYVpA6i (@StephenVLiu)

Updates to the @ASCO Living Guidelines on Therapy for Stage IV NSCLC with Driver Alterations now @JCO_ASCO. Additions include amivantamab and mobocertinib for #EGFR exon 20 insertion NSCLC and sotorasib for #KRAS G12C NSCLC. https://t.co/NdWku4z9BU (@StephenVLiu)

Latest living guideline update on stage IV NSCLC just published. Listen to Dr. @ns_chd share the new updates - including second-line options for patients with EGFR exon 20 insertions or KRAS G12C mutations - & the rationale in our latest podcast episode https://t.co/yIzwf6akKb (@BrittanyEHarvey)

Dr. George Simon is presenting several paths in NSCLC (RET, BRAF, NTRK, HER2, KRAS). A lesson from ASCO: if an NSCLC tumor has KRAS G12C and another KRAS present, sotorasib will not work. The importance of co-mutations nowadays. @MCIStrong @ASCO @IASLC @MoffittNews @LuisRaezMD (@EdgardoSantosMD)

👀 Check out what’s popular this week in #JCOPO: Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant #NSCLC ➡️ https://t.co/4pghKnMZFP @rohit_thum @RielyMD @KCArbourMD #lcsm (@JCOPO_ASCO)

Cracking KRASG12C across all solid tumors: the new kid on the block for tissue-agnostic precision medicine https://t.co/36kOZ8bPEi... https://t.co/XyNcxEXxRm Now open @MDAndersonNews 👉🏽 a phase 1b trial of Adagrasib in KRAS G12C mutant #PancreaticCancer https://t.co/whJlkT6aXi (@Aiims1742)

Cracking KRASG12C across all solid tumors: the new kid on the block for tissue-agnostic precision medicine - ESMO Open ⁦@ESMO_Open⁩ ⁦@myESMO⁩ ⁦@OncoAlert⁩ https://t.co/c9tG8T7FJ4 (@VivekSubbiah)

Commentary on @JCO_ASCO paper Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation @GIcancerDoc @Aiims1742 @DrShubhamPant @TumorBoardTues @MPishvaian Thanks to @cczielinski for invite to write the editorial @weoncologists @ESMO_Open https://t.co/erYeW4KdD0 (@VivekSubbiah)

Kicking off day ✌🏽 of #DAVAHawaiiLung discussing emerging KRAS targeting agents. @RielyMD says it best: “It’s time to move beyond KRAS G12C.” #lcsm (@esinghimd)

Great paper from @rohit_thum and @KCArbourMD from @MSK_DeptOfMed @MSKCancerCenter Shows a couple of key findings for patients with KRAS G12C mutated NSCLC treated with sotorasib. https://t.co/QOhzCq4z9i @JCOPO_ASCO (@RielyMD)

Our study of clinical/genomic predictors of response and toxicity to sotorasib in KRAS G12C+ NSCLC we recently presented at #ASCO23 is out today @JCOPO_ASCO. Thanks to @RielyMD @KCArbourMD @bherzbergmd @JSabari for the mentorship and collaboration! https://t.co/gQJsZFzbhI (@rohit_thum)

Are you ready for targeted neoadjuvant therapy for EGFR and KRAS G12C mutant NSCLC? @MNagasaka and @kamarroneMD discuss ongoing trials with these new treatment paradigms. More discussion to come later in the program! #DAVAHawaiiLung https://t.co/CSNPUHba3j (@KE_Gallaway)

📢 Pleased to share this link 👇👇 that give you free access to our article "Severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti-PD(L)1 and sotorasib therapy in KRASG12C-mutant lung cancer" @JTOonline https://t.co/ag88PwcEVL (@MDuruisseaux)

WATCH: @DrShubhamPant, of @MDAndersonNews, discusses the investigation of adagrasib in the treatment of patients with KRAS G12C–mutated advanced solid tumors. #crcsm https://t.co/H1vDezOWOg (@OncLive)

#ILCC23 what to do at the time of PD from acquired resistance in oncogene-driven NSCLC? Empiric or biomarker-related decision making? Is paradigm different for EGFR-mutated vs ALK vs METex14 vs KRAS G12C? Come listen to our panel discussion @HwakeleeMD @DrRoyHerbstYale @gotoPER (@drgandara)

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS G12C Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases @JCO_ASCO #Precisionmedicine https://t.co/hDyyoGFtXh (@VivekSubbiah)

New @JCO_ASCO study on CNS efficacy of adagrasib in #KRAS G12C #lungcancer. IC-ORR 42% in untreated brain mets and mDOR of 12.7 months, though mPFS of 5.4 months. Suspect mismatch likely driven by diverse #Kras resistance. @OncoAlert @KRASKickers #lcsm 👉🏽https://t.co/3y6NVVwA19 (@TejasPatilMD)

Nice to see this in print. Cohort of patients with KRAS G12C NSCLC with untreated brain metastases prospectively enrolled and treated with adagrasib. Clear CNS activity. https://t.co/g27K6lCg8V @JSabari @JCO_ASCO @ShirishGadgeel @DrJaredWeiss @AlexSpiraMDPhD (@RielyMD)

8/21 #TumorBoardTuesday ✅Some of the exciting NOVEL data🗣️at #ASCO23 in #PancreaticCancer was with KRAS🎯💊 ➡️@DrShubhamPant🗣️ an update on 57 Pts (21 w/ PDAC) Txed w/ the KRASG12C⛔️adagrasib 👉ORR 35% overall 👉N/V/D in ~50% of Pts - almost all Grade ≤2 👉6% Gr 3 fatigue (@MPishvaian)

@DrShubhamPant, a member of our Conquering KRAS in Pancreatic Cancer TeamLab, presented Updates on Abstract 425082: Krystal-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Advanced Solid Tumors Harboring a KRASG12C Mutation. (@break_cancer)

🔥Response to (K)RASG12C & EGFR Inhibition in a Patient With NRASG12C-Mutated #colorectalcancer @JCOPO_ASCO https://t.co/WNcfpzgsUJ 😅good to know... 👉extension of inclusion criteria for trials to all Ras genes could be considered @myESMO @OncoAlert https://t.co/HSTjyjxsyl (@ArndtVogel)

🔥Response to (K)RASG12C & EGFR Inhibition in a Patient With NRASG12C-Mutated #colorectalcancer @JCOPO_ASCO https://t.co/WNcfpzgsUJ 😅good to know 👉extension of inclusion criteria for trials to all Ras genes could be considered @myESMO @OncoAlert https://t.co/Vu4RSrJAFR (@ArndtVogel)

@AACR @CCR_AACR 🚨 📚: Early ctDNA changes of KRAS G12C in Phase 2 trial of adagrasib 🧪 for advanced #KRASG12C mutant #LCSM 🩺. @KRASKickers Max response seen in first ~3 weeks 🕐. 89.7% patients showed >90% ctDNA decrease 📉 84.6% achieved complete clearance by cycle 2 🧪.… https://t.co/NPwRU31v6L (@ADesaiMD)

AVM: SCARLET Study WJOG14821L Single arm Ph2 sotorasib + chemo in KRAS G12c nonsquamous mNSCLC 🔹N=30, chemo & KRAS inhibitor naive 🔹1ry endpoint ORR: 88.9% No diff in ORR by PD-L1 expression mPFS and mOS NR but limited f/u at analysis of only 4 mo #LCSM #ASCO23 @AnaVManana (@OncLive)

In a session on #LungCancer at #ASCO23, @LuisPaz_Ares shares biomarker analyses of CodeBreaK 200, a phase 3 trial of investigating pretreated KRAS G12C-mutated advanced #NSCLC: https://t.co/aVVKyvGlF4 #CRUKFunded (@CRUKresearch)

@BasselElRayesMD shows: 1) PhIII SOLSTICE in lonsurf+bev = cape-bev #1L mCRC ineligible for intensive chemo, 2) CodeBreaK 101 soto+FOLFIRI-pmab in pretreated #KRASG12C mCRC ORR 55% (0 CRs), 3) FIH PhI WNT/porcupine inh CGX1321+pembro 71% SD w/RSPO/RNF43 fusion #ASCO23 @OncoAlert (@jgong15)

#ASCO23 @ASCO #LCSM "Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status" - thrilled to present this today with @JPatelMD @TempusLabs @OncoAlert Poster Board#124 (@CharuAggarwalMD)

Real-world outcomes of 1L immune checkpoint inhibitors +/- chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status [2023] @CharuAggarwalMD et al. #ASCO23 Abst 9136, Poster 124 https://t.co/u4R1ToT6m8 #lcsm #ImmunoOnc #PrecisionMedicine @PennCancer @TempusLabs (@mtmdphd)

#ASCO23 @ASCO Presenting on real world outcomes of 1L ICI in KRASG12C MT #NSCLC ➡️ Pts with KRASMT TPS<1 have worse OS! ➡️ Co-mutations w/ STK11/ KEAP assoc with worse OS ⁦@OncoAlert⁩ ⁦@TempusLabs⁩ ⁦@JPatelMD⁩ (@CharuAggarwalMD)

#ASCO23 @WuGiOnc from @MayoClinic teaching👩‍🏫us about HER2, KRASG12C, NTRK, and RET🎯💊 for patients with metastatic #colorectalcancer Even though these are uncommon findings, 🙏🙏🙏PLEASE🧬test ALL advanced patients to give them more treatment options‼️ (@MPishvaian)

A few @eaonc poster presentations in #lungcancer (current trials) Sun 6/4 1st line Durvalumab w/chemo in advanced pleural #mesothelioma @FordePatrick ECOG-ACRIN LUNG-MAP substudy: phase II - sotorasib in prev treated pts with #KRAS G12C @SukiPaddaMD #LCSM @KRASKickers #ASCO23 (@jillfeldman4)

LCVL Español: https://t.co/nXzXukXCvE En este video, la Dra. @Latinamd analiza las opciones de terapia dirigida para pacientes con NSCLC KRAS G12C+, incluidos los resultados de los ensayos CodeBreak y Krystal. Para más información visita: https://t.co/3VETMT8MBC. (@cancerGRACE)

Breaking down the hidden CODE ! Biomarker analysis of CodeBreak 100 ⬇️ KRAS G12C mut NSCLC 🎯Sotarasib >12 mo PFS benefit in only 23% Who benefits ? ➡️Wild type KEAP1 (STK11 mut/wt) ➡️PI3K, PDGFR, RET mutations ➡️Lower baseline ctDNA ➡️ @JCO_ASCO @oncologician @OncBrothers (@shikharkumar89)

Phase II study of S1507: docetaxel + trametinib in #KRAS NSCLC @CCR_AACR from Drs. @ShirishGadgeel @karenkellymd et al. Overall RR 34% (28% in KRAS G12C) with mPFS 4.1m and mOS 10.9m. Outcomes worse with TP53 co-mutations. https://t.co/lXlchELZrm (@StephenVLiu)

#ASCO23 @ASCO Abs#9016 Intracranial efficacy of sotorasib vs docetaxel #KRAS G12C #NSCLC - look out for data as a #LBA @peters_solange @Dingemans_AnneM @KRASKickers @OncoAlert @HemOncToday (@CharuAggarwalMD)

In this episode of #LungCancerConsidered, the @IASLC podcast, I discuss management of #KRAS G12C NSCLC with Drs. @MLJohnsonMD2 and @FSkoulidis. Rapidly evolving space - hear what these experts have to say about the field! #LCSM https://t.co/tyUzHu8cng (@StephenVLiu)

Real world outcomes with docetaxel in #KRAS G12C NSCLC reported @LungCaJournal by Drs. @JhanelleGray @MLJohnsonMD2 et al. In 295 pts, rwPFS 3.4m and rwOS 6m with docetaxel (many with ramucirumab). Outcomes much worse than trial control arms suggest. https://t.co/eFc4Q09aOE (@StephenVLiu)